<DOC>
	<DOC>NCT02031523</DOC>
	<brief_summary>It is a multi-center, double -blind, placebo -controlled, randomized post-marketing study in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo.</brief_summary>
	<brief_title>Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis</brief_title>
	<detailed_description>Sanjie Analgesic Capsule is a Chinese Traditional Patent Medicine. It is a botanical extract from the raw materials of the Resina Draconis , Panax Notoginseng, fritillary bulb and coix seed, which are derived from a classic prescription of traditional Chinese medicine. Sanjie Analgesic Capsule was approved by CFDA in 2004, produced by means of modern technology by Jiangsu Kanion Pharmaceutical Co., Ltd. The study is a multi-center, double -blind, placebo-controlled, randomized in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic Capsule versus subjects treated with placebo.</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Subjects have a diagnosis of endometriosis by laparoscopy within 5 years prior to signing ICF, main complain of dysmenorrhea (or menstrual pain or painful periods) and with VAS score of 4 or above; Endometriosis combined with uterine adenomyosis is included. Female between the ages of 18 and 45 years old; Regular menstrual period, menstrual cycle falls in the ranging from 28 to 30 days; No pregnancy planning during taking study medication; use (or have their partner use) an acceptable method of birth control within the projected duration of the study ; Subjects must sign ICF and agree for follow up. Genital cancer or other malignant tumor; Adnexal masses≥5cm; Uterine myoma≥3cm; Suffering from cardiovascular, hepatic, renal or hematopoietic system disease or mental illness; Receiving hormone therapy within 3 months prior to signing ICF; Receiving surgical treatment for endometriosis within 3 months prior to signing ICF; Subjects have a plan of pregnancy, being pregnant, breastfeeding during recent 3 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>endometriosis</keyword>
	<keyword>dysmenorrhea</keyword>
	<keyword>Sanjie analgesic capsule</keyword>
	<keyword>effect/safety</keyword>
</DOC>